Neuroblastic Tumor Recurrence Associated With Opsoclonus Myoclonus Ataxia Syndrome Relapse a Decade After Initial Resection and Treatments

Micky K. Bacchus, David S. Anderson, Esther R. Berko, Lisa J. States, Rochelle Bagatell, Sarah E. Hopkins, Vandana Batra

Research output: Contribution to journalArticlepeer-review

Abstract

Opsoclonus myoclonus ataxia syndrome (OMAS) is a rare disorder that causes significant neurodevelopmental sequelae in children. Approximately half of pediatric OMAS cases are paraneoplastic, typically associated with localized neuroblastic tumors. Since early persistence or relapse of OMAS symptoms is common even after tumor resection, OMAS relapses may not routinely prompt reevaluation for recurrent tumors. We report a 12-year-old girl with neuroblastic tumor recurrence associated with OMAS relapse a decade after initial treatment. Providers should be aware of tumor recurrence as a trigger for distant OMAS relapse, raising intriguing questions about the role of immune surveillance and control of neuroblastic tumors.

Original languageEnglish
Pages (from-to)152-154
Number of pages3
JournalJournal of Pediatric Hematology/Oncology
Volume45
Issue number3
DOIs
StatePublished - 1 Apr 2023
Externally publishedYes

Keywords

  • ataxia
  • myoclonus
  • neuroblastoma
  • opsoclonus
  • pediatrics

Fingerprint

Dive into the research topics of 'Neuroblastic Tumor Recurrence Associated With Opsoclonus Myoclonus Ataxia Syndrome Relapse a Decade After Initial Resection and Treatments'. Together they form a unique fingerprint.

Cite this